Greenwich LifeSciences Valuation Multiples

Greenwich LifeSciences Overview

About Greenwich LifeSciences

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Founded

2006

HQ

Employees

8

Website

greenwichlifesciences.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

Net Income: ($16M)

EV

$380M

Valuation Multiples

Multiples.vc

Start free trial

Greenwich LifeSciences Financials

Greenwich LifeSciences reported last 12-month revenue of —.

In the same LTM period, Greenwich LifeSciences generated had net loss of ($16M).

Greenwich LifeSciences P&L

In the most recent fiscal year, Greenwich LifeSciences reported revenue of — and EBITDA of ($16M).

Greenwich LifeSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Greenwich LifeSciences Stock Performance

Greenwich LifeSciences has current market cap of $384M, and enterprise value of $380M.

Greenwich LifeSciences' stock price is $27.72.

Greenwich LifeSciences Valuation Multiples

Greenwich LifeSciences trades at (23.8x) EV/EBITDA.

Greenwich LifeSciences Financial Valuation Multiples

As of March 18, 2026, Greenwich LifeSciences has market cap of $384M and EV of $380M.

Equity research analysts estimate Greenwich LifeSciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Greenwich LifeSciences has a P/E ratio of (23.9x).

Greenwich LifeSciences Margins & Growth Rates

Greenwich LifeSciences' revenue in the last fiscal year grew by —.

Greenwich LifeSciences' revenue per employee in the last FY averaged $0.0M.

Greenwich LifeSciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Greenwich LifeSciences M&A Activity

Greenwich LifeSciences acquired XXX companies to date.

Last acquisition by Greenwich LifeSciences was on XXXXXXXX, XXXXX. Greenwich LifeSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Greenwich LifeSciences Investment Activity

Greenwich LifeSciences invested in XXX companies to date.

Greenwich LifeSciences made its latest investment on XXXXXXXX, XXXXX. Greenwich LifeSciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).